Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Next-Generation Biologics: Improving on Monoclonal Antibodies

Published by: Decision Resources

Published: Dec. 12, 2007 - 35 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

The Structure of an Antibody

Improving on Monoclonal Antibodies

Development

Manufacturing

Cost

Competition and Royalty Stacking

Delivery

Immunogenicity

Industry Interest and Clinical Development

Remaining Challenges for MAb Alternatives

Appendix A. Types of Biologic Alternatives to Therapeutic Monoclonal Antibodies

Tables

1. MAb Alternatives in Clinical Development

2. Licensing and Comarketing Deals Involving MAb Alternatives, 2000-2007

3. Acquisitions Involving MAb Alternatives, 1999-2007

Figures

1. Market Growth of Biotherapeutics and Small-Molecule Drugs, 2002-2006

2. Share of Monoclonal Antibodies in the Biologics Market, 2002-2008

3. Structure of an Antibody

4. MAb Alternatives by Development Stage, 2007

5. Deals Involving MAb Alternatives, 2000-2007

6. MAb Alternatives in Development, by Therapeutic Area, 2007

Abstract

Monoclonal antibodies (MAbs) have become the most successful platform for targeted biotherapeutics, demonstrating high affi nity and specifi city for their target and considerably lower toxicity than small-molecule drugs. Technological advances in the development and production of MAbs have revealed that antibody fragments and other smaller, less complex proteins have the potential to overcome many disadvantages of MAbs, and researchers have begun to explore the therapeutic potential of peptides and nucleic acids as alternatives to MAbs. The small biotechnology companies that sprang up to commercialize these emerging technologies have benefi ted from a fl urry of recent licensing and development deals and acquisitions as Big Pharma begins to see the potential of MAb alternatives and hurries to get in on the action.

Get the Answers You Need to Shape Your Strategy
  • The biotechnology and pharmaceutical industries are turning to MAb alternatives as the next generation of targeted biotherapeutics.
  • What advantages do small MAb alternatives offer over large MAbs?
  • What disadvantages do these novel agents have?
  • What choices are possible in the manufacture and formulation of MAb alternatives?
  • Because of the high price of biotherapeutic agents, health care payers, government, and patients are exerting pressure on companies to lower the prices of their drugs.
  • How could MAb alternatives help companies respond to this pressure and remain profi table?
  • How fast and cost-effectively can these agents be brought to market?
  • Although some MAb alternatives are already on the market, and despite growing industry confi dence in these novel technologies, the road ahead will not be easy.
  • Why is small size not always better?
  • What clinical disadvantages may be inherent in MAb alternatives?
  • How will the anticipated regulatory guidance on approval of biogenerics in the United States affect the market for MAb alternatives?
Scope

Biotechnology overview:
  • Biotherapeutics
  • monoclonal antibodies (MAbs)
  • emerging MAb alternatives.
Industry overview:
  • Biotech and Big Pharma companies
  • marketed MAb alternatives
  • molecules in development
  • by therapeutic area
  • industry deals and acquisitions, 2000-2007.
  • Production of MAb alternatives
  • Biological processes versus cell-free or chemical synthesis
  • formulation
  • reducing immunogenicity
  • cost
  • developmental timelines.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


advertise with us

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008